Is there a role for VeriStrat testing in determining when to use an EGFR TKI in previously treated squamous cell NSCLC?

Although PD-1 inhibitors are now standard of care for second-line therapy of advanced NSCLC, there remains the question of which therapy is best to use after failure of nivolumab or pembrolizumab. LUX-Lung 8 (http://www.ncbi.nlm.nih.gov/pubmed/26156651) recently demonstrated a survival advantage for afatinib over erlotinib in previously treated advanced squamous-cell NSCLC. Would the results of VeriStrat testing influence you to choose an EGFR TKI over chemotherapy in this setting?